» Articles » PMID: 34067705

Beneficial Modulation of Lipid Mediator Biosynthesis in Innate Immune Cells by Antirheumatic Glycosides

Overview
Journal Biomolecules
Publisher MDPI
Date 2021 Jun 2
PMID 34067705
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

glycosides (TWG) is a traditional Chinese medicine with effectiveness against rheumatoid arthritis (RA), supported by numerous clinical trials. Lipid mediators (LM) are biomolecules produced from polyunsaturated fatty acids mainly by cyclooxygenases (COX) and lipoxygenases (LOX) in complex networks which regulate inflammation and immune responses and are strongly linked to RA. The mechanism by which TWG affects LM networks in RA treatment remains elusive. Employing LM metabololipidomics using ultra-performance liquid chromatography-tandem mass spectrometry revealed striking modulation of LM pathways by TWG in human monocyte-derived macrophage (MDM) phenotypes. In inflammatory M1-MDM, TWG (30 µg/mL) potently suppressed agonist-induced formation of 5-LOX products which was confirmed in human PMNL and traced back to direct inhibition of 5-LOX (IC = 2.9 µg/mL). TWG also efficiently blocked thromboxane formation in M1-MDM without inhibiting other prostanoids and COX enzymes. Importantly, in anti-inflammatory M2-MDM, TWG (30 µg/mL) induced pronounced formation of specialized pro-resolving mediators (SPM) and related 12/15-LOX-derived SPM precursors, without COX and 5-LOX activation. During MDM polarization, TWG (1 µg/mL) decreased the capacity to generate pro-inflammatory 5-LOX and COX products, cytokines and markers for M1 phenotypes. Together, suppression of pro-inflammatory LM but SPM induction may contribute to the antirheumatic properties of TWG.

Citing Articles

Targeting dysregulated intracellular immunometabolism within synovial microenvironment in rheumatoid arthritis with natural products.

Hu S, Lin Y, Tang Y, Zhang J, He Y, Li G Front Pharmacol. 2024; 15:1403823.

PMID: 39104392 PMC: 11298361. DOI: 10.3389/fphar.2024.1403823.


A comprehensive review of hook. f. in the treatment of rheumatic and autoimmune diseases: Bioactive compounds, mechanisms of action, and future directions.

Shan Y, Zhao J, Wei K, Jiang P, Xu L, Chang C Front Pharmacol. 2023; 14:1282610.

PMID: 38027004 PMC: 10646552. DOI: 10.3389/fphar.2023.1282610.


Establishment and Characterization of Mild Atopic Dermatitis in the DNCB-Induced Mouse Model.

Riedl R, Kuhn A, Rietz D, Hebecker B, Glowalla K, Peltner L Int J Mol Sci. 2023; 24(15).

PMID: 37569701 PMC: 10418750. DOI: 10.3390/ijms241512325.


Modulation of Inflammation-Related Lipid Mediator Pathways by Celastrol During Human Macrophage Polarization.

Zhang K, Jordan P, Pace S, Hofstetter R, Werner M, Chen X J Inflamm Res. 2022; 15:3285-3304.

PMID: 35676971 PMC: 9169975. DOI: 10.2147/JIR.S356964.


Shifting the Biosynthesis of Leukotrienes Toward Specialized Pro-Resolving Mediators by the 5-Lipoxygenase-Activating Protein (FLAP) Antagonist BRP-201.

Kretzer C, Jordan P, Bilancia R, Rossi A, Gur Maz T, Banoglu E J Inflamm Res. 2022; 15:911-925.

PMID: 35173459 PMC: 8842732. DOI: 10.2147/JIR.S345510.

References
1.
Jordan P, Gerstmeier J, Pace S, Bilancia R, Rao Z, Borner F . Staphylococcus aureus-Derived α-Hemolysin Evokes Generation of Specialized Pro-resolving Mediators Promoting Inflammation Resolution. Cell Rep. 2020; 33(2):108247. PMC: 7729929. DOI: 10.1016/j.celrep.2020.108247. View

2.
Crofford L . Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013; 15 Suppl 3:S2. PMC: 3891482. DOI: 10.1186/ar4174. View

3.
Aletaha D, Smolen J . Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018; 320(13):1360-1372. DOI: 10.1001/jama.2018.13103. View

4.
Albert D, Zundorf I, Dingermann T, Muller W, Steinhilber D, Werz O . Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol. 2002; 64(12):1767-75. DOI: 10.1016/s0006-2952(02)01387-4. View

5.
Norling L, Headland S, Dalli J, Arnardottir H, Haworth O, Jones H . Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight. 2016; 1(5):e85922. PMC: 4855303. DOI: 10.1172/jci.insight.85922. View